Esperion Therapeutics, a biotech focused on developing a treatment for patients with elevated levels of low-density lipoprotein cholesterol, announced terms for its IPO on Wednesday. The Plymouth, MI-based company plans to raise $63 million by offering 4.5 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Esperion Therapeutics would command a market value of $197 million.
Esperion Therapeutics, which was founded in 1998, plans to list on the NASDAQ under the symbol ESPR. Esperion Therapeutics initially filed confidentially in April 2013. Credit Suisse and Citi are the joint bookrunners on the deal.
